One Percent Rule Checklist For Safer Forex Trading Risk 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
China’s AI Models Narrow the Gap With the West, Says Google DeepMind CEO 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Syrah Resources and Tesla Extend Deadline on Graphite Supply Dispute to March 
Boeing Reaches Tentative Labor Deal With SPEEA Workers After Spirit AeroSystems Acquisition 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Publishers Seek to Join Lawsuit Against Google Over Alleged AI Copyright Infringement 
Federal Judge Clears Way for Jury Trial in Elon Musk’s Fraud Lawsuit Against OpenAI and Microsoft 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
SEATTLE and SOUTH SAN FRANCISCO, Calif., April 20, 2017 -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on oncology, today announced that new and updated data from two ongoing clinical trials of CMB305 and G100, as well as translational data examining the association of immunological response with improved survival in CMB305 and LV305 patients, will be presented in an oral and two posters presentations at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2 - 6, 2017 in Chicago. The ASCO presentation details are as follows:
ORAL PRESENTATION
Immune response, safety, and survival impact from CMB305 in NY-ESO-1+ recurrent soft tissue sarcomas (STS)
| Abstract # 11006 |
| Session Title: Sarcoma |
| Date: Friday, June 2, 2017 |
| Time: 3 p.m. – 6 p.m. CT (oral session) |
| Location: S100bc |
| Presenter: Neeta Somaiah, M.D., Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center |
POSTER PRESENTATIONS
The Association of CMB305 or LV305-induced and baseline anti-NY-ESO-1 immunity with survival in recurrent cancer patients
| Abstract # 3090 |
| Session Title: Developmental Therapeutics—Immunotherapy |
| Date: Monday, June 5, 2017 |
| Time: 8 a.m. – 11:30 a.m. CT (poster session) |
| Location: Hall A |
| Presenter: Seth M. Pollack, M.D., Fred Hutchinson Cancer Research Center |
Intratumoral G100 to induce systemic immune responses and abscopal tumor regression in patients with follicular lymphoma
| Abstract # 7537 |
| Session Title: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia |
| Date: Monday, June 5, 2017 |
| Time: 8 a.m. – 11:30 a.m. CT (poster session) |
| Location: Hall A |
| Presenter: Christopher Flowers, M.D., Department of Hematology and Medical Oncology, Emory University School of Medicine |
Additional data than those included in the abstracts may be included in the presentations.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immuno-oncology clinical programs, are products of its two synergistic discovery platforms, ZVex and GLAAS, the fundamental technologies of which were licensed from the California Institute of Technology and the Infectious Disease Research Institute (IDRI), respectively. Immune Design has offices in Seattle and South San Francisco. For more information, please visit www.immunedesign.com.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Immune Design's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Immune Design's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Immune Design's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Immune Design assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Media Contact Julie Rathbun Rathbun Communications [email protected] 206-769-9219 Investor Contact Shari Annes Annes Associates [email protected] 650-888-0902
